OncLive Staff

A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.

Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.

In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.

The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.

Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.

First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.

Savolitinib received conditional NMPA approval in China for MET-amplified gastric or GEJ adenocarcinoma after prior systemic therapy, based on a 32.3% ORR.

Divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib in the phase III Krascendo 1 trial in previously treated KRAS G12C–mutant NSCLC.

Long-term follow-up from the REVIVE and THRIVE studies showed a low thromboembolic event rate with rusfertide in phlebotomy-dependent polycythemia vera.

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.

Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.

Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.

Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.

The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for stratifying risk in early-stage cutaneous melanoma.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Epcoritamab plus lenalidomide reduced the risk of disease progression or death vs R-GemOx in relapsed/refractory DLBCL in the EPCORE DLBCL-4 trial.

Elisrasib produced a 58.8% ORR and 12.2-month median PFS in KRAS G12C inhibitor–naive NSCLC and remained active in G12C inhibitor–refractory disease.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

SB27, a proposed pembrolizumab biosimilar, met primary end points in phase 1 pharmacokinetic and a phase 3 efficacy studies.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

The enzalutamide bioequivalent received tentative FDA approval, pending patent expiry on branded Xtandi before final marketing authorization.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.

Translational profiling tied CCR4 loss, IL enrichment, and BCL-2 upregulation to mogamulizumab resistance; venetoclax may be a combination partner.

In a phase 1 trial, duvelisib plus nivolumab produced a 26% overall response rate in relapsed/refractory cutaneous T-cell lymphoma but was limited by immune-mediated toxicities.

Real-world mogamulizumab reduced skin symptoms and improved health-related quality of life in patients with mycosis fungoides and Sézary syndrome.

CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.